[12] S. S. Abdool Karim and T. de Oliveira, “New SARS-CoV-2 variants – Clinical,

public health, and vaccine implications,” N. Engl. J. Med., vol. 384, no. 19,

pp. 1866–1868, 2021.

[13] J. Lopez Bernal, et al., “Effectiveness of Covid-19 vaccines against the B.1.617.2

(Delta) variant,” N. Engl. J. Med., vol. 385, no. 7, pp. 585–594, 2021.

[14] M. Coughlin, et al., “Generation and characterization of human monoclonal neu-

tralizing antibodies with distinct binding and sequence features against SARS

coronavirus using XenoMouse,” Virology, vol. 361, no. 1, pp. 93–102, 2007.

[15] A. Tarke, et al., “Comprehensive analysis of T cell immunodominance and im-

munoprevalence of SARS-CoV-2 epitopes in COVID-19 cases,” bioRxiv, vol. 2,

no. 2, pp. 1–15, 2021. https://doi.org/10.1016/j.xcrm.2021.100204

[16] M. Liao, et al., “Single-cell landscape of bronchoalveolar immune cells in patients

with COVID-19,” Nat. Med., vol. 26, no. 6, pp. 842–844, 2020.

[17] T. C. Williams and W. A. Burgers, “SARS-CoV-2 evolution and vaccines: Cause

for concern?” Lancet Respir. Med., vol. 9, no. 4, pp. 333–335, 2021.

[18] Y. H. Chung, et al., “COVID-19 vaccine frontrunners and their nanotechnology

design,” ACS Nano, vol. 14, no. 10, p. 12522–12537, 2020.

[19] B. Greenwood, “The contribution of vaccination to global health: Past, present and

future,” Philos. Trans. R Soc. Lond B Biol. Sci., vol. 369, no. 1645, p. 20130433, 2014.

[20] K. Singh and S. Mehta, “The clinical development process for a novel preventive

vaccine: An overview,” J. Postgrad. Med., vol. 62, no. 1, pp. 4–11, 2016.

[21] O. Sharma, et al., “A review of the progress and challenges of developing a vaccine

for COVID-19,” Front. Immunol., vol. 11, p. 585354, 2020.

[22] B. S. Graham, “Rapid COVID-19 vaccine development,” Science, vol. 368, no.

6494, pp. 945–946, 2020.

[23] W. S. Lee, et al., “Antibody-dependent enhancement and SARS-CoV-2 vaccines

and therapies,” Nat. Microbiol., vol. 5, no. 10, pp. 1185–1191, 2020.

[24] Organization, W.H. “COVID-19 Vaccine Tracker and Landscape,” 2021 October 5,

2021 [cited 2021 October 7, 2021]; Available from: https://www.who.int/

publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

[25] S. A. Mendonca, et al., “Adenoviral vector vaccine platforms in the SARS-CoV-2

pandemic,” NPJ Vaccines, vol. 6, no. 1, p. 97, 2021.

[26] M. Brisse, et al., “Emerging concepts and technologies in vaccine development,”

Front. Immunol., vol. 11, p. 583077, 2020.

[27] U. Sahin, K. Kariko, and O. Tureci, “mRNAbasedtherapeutics–developing a new

class of drugs,” Nat. Rev. Drug Discov., vol. 13, no. 10, p. 759–780, 2014.

[28] L. Schoenmaker, et al., “mRNA-lipid nanoparticle COVID-19 vaccines: Structure

and stability,” Int. J. Pharm., vol. 601, p. 120586, 2021.

[29] N. Pardi, et al., “mRNA vaccines – a new era in vaccinology,” Nat. Rev. Drug

Discov., vol. 17, no. 4, pp. 261–279, 2018.

[30] Y. Watanabe, et al., “Site-specific glycan analysis of the SARS-CoV-2 spike,”

Science, vol. 369, no. 6501, pp. 330–333, 2020.

[31] S. P. Kaur and V. Gupta, “COVID-19 Vaccine: A comprehensive status report,”

Virus Res., vol. 288, p. 198114, 2020.

[32] F. P. Polack, et al., “Safety and efficacy of the BNT162b2 mRNA Covid-19

Vaccine,” N. Engl. J. Med., vol. 383, no. 27, pp. 2603–2615, 2020.

[33] Committee for Medicinal Products for Human Use (CHMP), E.M.A., “Assessment

report, Comirnaty, Common name: COVID-19 mRNA vaccine (nucleoside-modified),

Procedure No. EMEA/H/C/005735/0000”, E.M. Agency, Editor, p. 140, 2021.

[34] Z. Kis, C. Kontoravdi, R. Shattock & N. Shah, “Correction: Resources, production

scales and time required for producing RNA vaccines for the global pandemic demand

(Vaccines, (2021), 9, 1, 10.3390/vaccines9010003),” Vaccines vol. 9, 1–14, 2021.

312

Bioprocessing of Viral Vaccines